TY - JOUR
T1 - Venom allergen immunotherapy
AU - Golden, David B.K.
N1 - Funding Information:
From the Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland DBK Golden has received honorariums from ALK, Kaleo, Regeneron and Allergy Therapeutics Funding support provided by ALK through an unrestricted educational grant to the American Association of Certified Allergists (AACA). The AACA had full responsibility for the selection of topics and authors, as well as publisher oversight. This manuscript is part of the Allergy & Asthma Proceedings collection of published works referred to as the “Allergen Immunotherapy (AIT) Primer.” The contents of this work reflects the opinion(s) of the author(s) and is not intended to replace published guidelines or the clinician’s medical advice in the doctor-patient relationship Address correspondence to David Golden, M.D., 5501 Hopkins Bayview Circle, Baltimore, Maryland 21224 E-mail address: dgolden1@jhmi.edu Copyright © 2022, OceanSide Publications, Inc., U.S.A.
Publisher Copyright:
Copyright © 2022, OceanSide Publications, Inc., U.S.A.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Venom immunotherapy (VIT) with Hymenoptera venom extracts is highly effective in preventing large local, systemic allergic, and anaphylactic reactions to insect stings. VIT is not required for patients with cutaneous systemic or large local allergic reactions to stings because it is uncommon for reactions to become more severe. The clinical history, with confirmatory skin or serum tests for venom IgE, can clarify the risk for future anaphylaxis and the need for VIT. For initial treatment, rush regimens are recommended because they have the same or less risk of systemic reactions than slower traditional regimens. VIT is relatively safe with a low incidence of systemic reactions. Injection-site reactions can be bothersome but do not predict systemic reactions to venom injections. Patients who need VIT should be screened for baseline serum tryptase and possible underlying mast cell disorders. VIT can be discontinued after five years in most patients, but those with known high-risk factors should continue VIT indefinitely.
AB - Venom immunotherapy (VIT) with Hymenoptera venom extracts is highly effective in preventing large local, systemic allergic, and anaphylactic reactions to insect stings. VIT is not required for patients with cutaneous systemic or large local allergic reactions to stings because it is uncommon for reactions to become more severe. The clinical history, with confirmatory skin or serum tests for venom IgE, can clarify the risk for future anaphylaxis and the need for VIT. For initial treatment, rush regimens are recommended because they have the same or less risk of systemic reactions than slower traditional regimens. VIT is relatively safe with a low incidence of systemic reactions. Injection-site reactions can be bothersome but do not predict systemic reactions to venom injections. Patients who need VIT should be screened for baseline serum tryptase and possible underlying mast cell disorders. VIT can be discontinued after five years in most patients, but those with known high-risk factors should continue VIT indefinitely.
UR - http://www.scopus.com/inward/record.url?scp=85133752700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133752700&partnerID=8YFLogxK
U2 - 10.2500/aap.2022.43.210109
DO - 10.2500/aap.2022.43.210109
M3 - Article
C2 - 35818146
AN - SCOPUS:85133752700
SN - 1088-5412
VL - 43
SP - 339
EP - 343
JO - New England and regional allergy proceedings
JF - New England and regional allergy proceedings
IS - 4
ER -